Advertisement

Racial Disparities in HIV and Liver Disease

  • Nyingi M. Kemmer
Chapter

Abstract

Based on the recent Center of Disease Control (CDC) report, an estimated 1.1 million persons in the USA are infected with the human immunodeficiency virus (HIV). Several US-based population studies have consistently shown a significant ethnic variation in HIV prevalence, with ethnic minorities accounting for about 70% of those living with HIV. In 1997, for the purposes of federal statistics reporting, the Office of Management and Budget revised the classification of individuals by race and ethnicity. The revision identified five racial and two ethnic groups. The racial categories are as follows: (1) White, (2) Black or African American, (3) Asian, (4) Native Hawaiian or other Pacific Islander, and (5) American Indian or Alaskan Native; the ethnic categories are as follows: (1) Hispanic or Latino and (2) non-Hispanic/Latino. Owing to the lack of consistency in the classification across published studies, in this review ethnicity and race are used interchangeably. Ethnicity/race will be categorized as (1) White or Caucasian, (2) Black or African American, (3) Hispanic or Latino, (4) Asian, and (5) others.

Keywords

Human Immunodeficiency Virus Sustained Virologic Response African American Human Immunodeficiency Virus Population Human Immunodeficiency Virus Coinfection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    CDC: Centers for disease control and prevention. 2010.Google Scholar
  2. 2.
    Oramasionwu CU, Hunter JM, Skinner J, Ryan L, Lawson KA, Brown CM, et al. Black race as a predictor of poor health outcomes among a national cohort of HIV/aids patients admitted to us hospitals: a cohort study. BMC Infect Dis. 2009;9:127.PubMedCrossRefGoogle Scholar
  3. 3.
    Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol. 2010;8:183–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic patients with aids. J Natl Med Assoc. 2007;99:1381–5.PubMedGoogle Scholar
  5. 5.
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41:372–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50:464–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209–16.PubMedCrossRefGoogle Scholar
  10. 10.
    McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:365–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44:1026–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult aids clinical trials group. Clin Infect Dis. 2002;34:831–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Kim JH, Psevdos G, Suh J, Sharp VL. Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York city, United States. World J Gastroenterol. 2008;14:6689–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Spradling PR, Richardson JT, Buchacz K, Moorman AC, Finelli L, Bell BP, et al. Trends in hepatitis C virus infection among patients in the HIV outpatient study, 1996–2007. J Acquir Immune Defic Syndr. 2010;53:388–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.PubMedGoogle Scholar
  17. 17.
    Shores NJ, Maida I, Perez-Saleme L, Nunez M. Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. J Int Assoc Physicians AIDS Care (Chic). 2010;9:15–9.CrossRefGoogle Scholar
  18. 18.
    Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol. 2002;97:700–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Lepe R, Layden-Almer JE, Layden TJ, Cotler S. Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat. 2006;13:116–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Brau N, Rodriguez-Torres M, Prokupek D, Bonacini M, Giffen CA, Smith JJ, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39:989–98.PubMedCrossRefGoogle Scholar
  21. 21.
    Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, et al. Therapeutic response to peg-ifn-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS. 2009;23:2439–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Merriman NA, Porter SB, Brensinger CM, Reddy KR, Chang KM. Racial difference in mortality among U.S. Veterans with HCV/HIV coinfection. Am J Gastroenterol. 2006;101:760–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen MH, Grey D, Cook JA, Anastos K, Seaberg E, Augenbraun M, et al. Awareness of hepatitis C infection among women with and at risk for HIV. J Gen Intern Med. 2007;22:1689–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Butt AA, Tsevat J, Leonard AC, Shaikh OS, McMahon D, Khan UA, et al. Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis. 2009;13:449–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Vellozzi C, Buchacz K, Baker R, Spradling PR, Richardson J, Moorman A, et al. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV outpatient study (HOPS), 1999–2007. J Viral Hepat. 2010;18(5):316–24.CrossRefGoogle Scholar
  27. 27.
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology. 2007;132:733–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Persico M, Capasso M, Russo R, Persico E, Croce L, Tiribelli C, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut. 2008;57:507–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim KA, Lin W, Tai AW, Shao RX, Weinberg E, De Sa Borges CB, et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol. 2009;50:705–11.PubMedCrossRefGoogle Scholar
  32. 32.
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in il28b is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45. 1345.e1–17.PubMedCrossRefGoogle Scholar
  33. 33.
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in il28b and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.PubMedCrossRefGoogle Scholar
  34. 34.
    Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV outpatient study, 1996–2007. J Viral Hepat. 2010;17(12):879–86.PubMedCrossRefGoogle Scholar
  35. 35.
    Landrum ML, Fieberg AM, Chun HM, Crum-Cianflone NF, Marconi VC, Weintrob AC, et al. The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults. PLoS One. 2010;5:e8687.PubMedCrossRefGoogle Scholar
  36. 36.
    French AL, Lin MY, Evans CT, Benning L, Glesby MJ, Young MA, et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis. 2009;49:148–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis. 2003;188:571–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. Military cohort of HIV-infected individuals: another benefit of HAART in those with preserved cd4 count. Vaccine. 2009;27:4731–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med. 2004;164:2349–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2:820–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Brau N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.PubMedCrossRefGoogle Scholar
  42. 42.
    Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation. 2007;84:563–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Duclos-Vallee JC, Teicher E, Vittecoq D, Samuel D. Liver transplantation for patients infected with both HIV and HCV or HIV and HBV. Med Sci (Paris). 2007;23:723–8.CrossRefGoogle Scholar
  44. 44.
    Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of united network for organ sharing database. Transplantation. 2008;85:359–68.PubMedCrossRefGoogle Scholar
  45. 45.
    de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983–93.PubMedCrossRefGoogle Scholar
  46. 46.
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.PubMedCrossRefGoogle Scholar
  47. 47.
    Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, et al. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl. 2009;15:1010–20.PubMedCrossRefGoogle Scholar
  48. 48.
    Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV–HBV coinfected transplant recipients. Am J Transplant. 2010;10(5):1268–75.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of CincinnatiCincinnatiUSA

Personalised recommendations